Welcome to our dedicated page for Maze Therapeutics SEC filings (Ticker: MAZE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Maze Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Maze Therapeutics's regulatory disclosures and financial reporting.
Maze Therapeutics, Inc. chief business and strategy officer Atul Dandekar reported a mix of equity awards, option exercise, and share sales. He received a grant of 38,000 stock options and 19,000 restricted stock units, each at an exercise or acquisition price of $0.00 per share.
On February 27, 2026, he exercised 7,500 stock options at $10.42 per share to acquire 7,500 shares of common stock, then sold 3,739 shares at a weighted average price of $45.134 and 3,761 shares at $45.7238. The sales were made under a Rule 10b5-1 trading plan adopted on September 29, 2025.
Following these transactions, he directly held 10,503 shares of common stock, 59,143 stock options and 19,000 restricted stock units. The new option award vests in 1/48 increments monthly starting April 1, 2026, while the RSUs vest in four annual tranches beginning March 1, 2027.
Maze Therapeutics, Inc. reported that Chief Executive Officer Jason V. Coloma received new equity awards. He was granted a stock option for 150,000 shares with a zero exercise price shown in the filing, vesting in 1/48 monthly tranches starting on April 1, 2026, as long as he remains in service.
Coloma was also granted 75,000 restricted stock units, each representing the right to receive one share of common stock upon settlement. These RSUs vest in four equal annual installments, with the first 1/4 vesting on March 1, 2027 and the remaining tranches vesting on each anniversary, subject to continued service. The RSUs do not expire; they either vest or are cancelled before vesting.
Maze Therapeutics insider awarded stock options and RSUs. On March 2, 2026, a reporting person who is a 10% owner and serves as President, R&D & CMO received 48,000 stock options with an exercise price of $45.61 per share, expiring on March 1, 2036. These options vest monthly over four years, with the first 1/48 tranche on April 1, 2026, contingent on continued service.
The insider was also granted 24,000 restricted stock units, each representing one share of common stock. This RSU award vests in four equal annual installments, starting on March 1, 2027, also subject to continued service. Unvested RSUs either vest on schedule or are cancelled before vesting.
Maze Therapeutics SVP, Finance Amy Bachrodt reported multiple equity transactions on March 2, 2026. She exercised a stock option for 5,000 shares of common stock at $10.42 per share and received a new stock option grant for 32,000 shares plus 16,000 restricted stock units, all held directly.
On the same date, she sold 1,300 shares of common stock at a weighted average price of $44.4414 and 3,700 shares at a weighted average price of $45.4694, in open‑market transactions under a Rule 10b5‑1 trading plan adopted on September 29, 2025. The footnotes note price ranges for these weighted averages and describe monthly vesting for the options and annual vesting tranches for the RSUs, subject to continued service.
Maze Therapeutics, Inc. received an updated Schedule 13G/A from a group of Frazier Life Sciences investment vehicles reporting significant ownership of its common stock. Frazier Life Sciences Public Fund, L.P. directly holds 4,342,266 shares of common stock, representing 9.0% of the class, based on 48,119,444 shares outstanding as of November 3, 2025.
Additional Frazier funds report smaller positions: Frazier Life Sciences X, L.P. holds 75,982 shares (0.2%) and Frazier Life Sciences XI, L.P. holds 149,026 shares (0.3%). Several affiliated Frazier Life Sciences XII entities report no common shares.
The filing notes that these figures exclude prefunded warrants. FLSPF holds warrants to purchase 1,702,935 shares, FLS X 54,280 shares, FLS XI 144,532 shares, and FLS XII 252,231 shares, each subject to a 9.99% beneficial ownership limitation that prevents any holder from exceeding that ownership threshold upon exercise. The reporting group certifies that the securities are not held for the purpose of changing or influencing control of Maze Therapeutics.
Maze Therapeutics, Inc. received an updated Schedule 13G/A from several affiliated Third Rock Ventures funds reporting their ownership of the company’s common stock. Third Rock Ventures IV, L.P. directly holds 4,473,958 shares of common stock, which represents approximately 9.3% of Maze’s outstanding shares based on 48,119,440 shares outstanding as of November 3, 2025. Third Rock Ventures V, L.P. directly holds 950,800 shares, representing about 2.0% of the outstanding stock on the same basis.
Related general partner entities (Third Rock Ventures GP IV, L.P., TRV GP IV, LLC, Third Rock Ventures GP V, L.P., and TRV GP V, LLC) may be deemed to share voting and dispositive power over these shares, but they report no sole voting or dispositive power. The reporting persons expressly disclaim the existence of a “group” for regulatory purposes.
Alphabet Inc. and its GV investment affiliates report a minority stake in Maze Therapeutics. As of December 31, 2025, they may be deemed to beneficially own 1,388,583 shares of Maze common stock, representing 2.9% of shares outstanding.
The holdings are split between GV 2019, L.P. with 784,019 shares (1.6%) and GV 2023, L.P. with 604,564 shares (1.3%), with control cascading through GV general partners to Alphabet subsidiaries and ultimately Alphabet Inc. The filing confirms ownership of 5% or less of the class.
Maze Therapeutics, Inc. has filed an automatic shelf registration and established an at-the-market offering program to sell up to $200,000,000 of common stock through Jefferies LLC as sales agent. Shares will be sold from time to time at prevailing market prices, with Jefferies earning up to 3% in commissions.
The company plans to use any net proceeds for general corporate purposes, including research and development, working capital, capital spending, and potential acquisitions. Maze is a clinical-stage biopharmaceutical company focused on precision medicines for kidney and metabolic diseases, and it had 48,076,885 common shares outstanding as of September 30, 2025.
Maze Therapeutics, Inc. entered into a senior secured term loan agreement with Hercules Capital providing up to $200.0 million in potential borrowing capacity. An initial $40.0 million tranche was funded at closing, generating approximately $38.4 million of net proceeds after fees.
The facility matures on February 1, 2031, carries a floating interest rate based on the Wall Street Journal prime rate with floors between 7.95% and 9.25%, and offers an interest-only period of up to 48 months, or up to 60 months if specified milestones are met. Repayments trigger an exit fee of 3.95% to 6.45% of principal, and early prepayments can incur premiums of up to 3.00% within the first 12 months.
The loan is secured by a first lien on substantially all of Maze’s assets and includes customary representations, covenants, financial tests, and events of default, including minimum unrestricted cash requirements tied to market capitalization and outstanding loan balances. Concurrently, the company terminated its prior Loan and Security Agreement with Banc of California and released that lender’s security interest in its assets.
Maze Therapeutics President, R&D & CMO Harold Bernstein reported an automatic stock transaction under a Rule 10b5-1 trading plan. On February 2, 2026, he exercised a stock option for 15,000 shares of common stock at an exercise price of $10.42 per share.
On the same date, he sold a total of 15,000 common shares in several market transactions at weighted average prices of $44.205, $45.8891, $46.3732 and $47.23 per share, with actual sale prices ranging from $44.15 to $47.17 per share. After these sales, he reported 0 shares of common stock directly owned and 297,407 stock options remaining, linked to an award that began vesting on October 3, 2023.